Clear Street’s Novo Nordisk NVO Stock Holding History

Clear Street’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-79,600	Closed	-$6.44M	–	1241
2023 Q2	$6.44M	Buy	+79,600	New	+$6.5M	0.06%	165

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Clear Street's NVO Position: Q2 2026 in Review

Clear Street increased its Novo Nordisk (NVO) stake by 15% in Q2 2026, buying an estimated $1.94M and bringing the position to 342,213 shares worth $16.4M. The position accounts for 0.04% of the portfolio, ranked #102.

Clear Street first reported a position in NVO in Q2 2023 and has held it in 5 quarters since. The position peaked at $56.4M in Q3 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Clear Street held 342,213 shares of Novo Nordisk worth $16.4M as of Q2 2026.
Clear Street bought 45,152 Novo Nordisk shares in Q2 2026, an estimated $1.94M.
Novo Nordisk made up 0.04% of Clear Street's portfolio in Q2 2026, its #102 holding.
Clear Street first reported a position in Novo Nordisk in Q2 2023 and has held it in 5 quarters since.
Clear Street's Novo Nordisk position peaked at $56.4M in Q3 2025.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.